Piramal Pharma Ltd approves Q2 FY27 results, reporting consolidated revenue of ₹2,617.06 crore and net profit of ₹5.03 crore
- Revenue rose 15.3% sequentially and 28.1% year on year.
- Net profit compared with losses of ₹69.38 crore in Q1 FY27 and ₹99.22 crore in Q2 FY26.
- No exceptional items were reported; statutory auditors’ limited review noted that some subsidiary results were not reviewed by auditors.
Original Filing: https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a6725b04-5153-4250-a753-78a0ad82d389.pdf